Search

Your search keyword '"Bertamini L"' showing total 3 results
Start Over Author "Bertamini L" Topic medicine
3 results on '"Bertamini L"'

1. Carfilzomib with cyclophosphamide and dexamethasone or lenalidomide and dexamethasone plus autologous transplantation or carfilzomib plus lenalidomide and dexamethasone, followed by maintenance with carfilzomib plus lenalidomide or lenalidomide alone for patients with newly diagnosed multiple myeloma (FORTE): a randomised, open-label, phase 2 trial

Author

Francesca Gay, Pellegrino Musto, Delia Rota-Scalabrini, Luca Bertamini, Angelo Belotti, Monica Galli, Massimo Offidani, Elena Zamagni, Antonio Ledda, Mariella Grasso, Stelvio Ballanti, Antonio Spadano, Michele Cea, Francesca Patriarca, Mattia D'Agostino, Andrea Capra, Nicola Giuliani, Paolo de Fabritiis, Sara Aquino, Angelo Palmas, Barbara Gamberi, Renato Zambello, Maria Teresa Petrucci, Paolo Corradini, Michele Cavo, Mario Boccadoro, Gay F., Musto P., Rota-Scalabrini D., Bertamini L., Belotti A., Galli M., Offidani M., Zamagni E., Ledda A., Grasso M., Ballanti S., Spadano A., Cea M., Patriarca F., D'Agostino M., Capra A., Giuliani N., de Fabritiis P., Aquino S., Palmas A., Gamberi B., Zambello R., Petrucci M.T., Corradini P., Cavo M., and Boccadoro M.

Subjects
Male, Antibodies, Monoclonal, Antineoplastic Combined Chemotherapy Protocols, Bortezomib, Combined Modality Therapy, Cyclophosphamide, Dexamethasone, Female, Follow-Up Studies, Hematopoietic Stem Cell Transplantation, Humans, Lenalidomide, Melphalan, Middle Aged, Multiple Myeloma, Oligopeptides, Prognosis, Survival Rate, Thalidomide, Transplantation, Autologous, chemistry.chemical_compound, Maintenance therapy, Monoclonal, Medicine, multiple myeloma, newly diagnosed, carfilzomib, cyclophosphamide, lenalidomide, dexamethasone, induction treatment, autologous stem-cell transplantation, maintenance treatment, phase 2, trial, Multiple myeloma, carfilzomib, trial, induction treatment, Oncology, Oligopeptide, newly diagnosed, Autologous, Human, medicine.drug, medicine.medical_specialty, Prognosi, autologous stem-cell transplantation, Antibodies, Follow-Up Studie, Internal medicine, Autologous transplantation, Transplantation, Antineoplastic Combined Chemotherapy Protocol, maintenance treatment, business.industry, medicine.disease, Settore MED/15, Carfilzomib, chemistry, phase 2, business
Abstract

Background: Bortezomib-based induction followed by high-dose melphalan (200 mg/m2) and autologous stem-cell transplantation (MEL200-ASCT) and maintenance treatment with lenalidomide alone is the current standard of care for young and fit patients with newly diagnosed multiple myeloma. We aimed to evaluate the efficacy and safety of different carfilzomib-based induction and consolidation approaches with or without transplantation and of maintenance treatment with carfilzomib plus lenalidomide versus lenalidomide alone in newly diagnosed multiple myeloma. Methods: UNITO-MM-01/FORTE was a randomised, open-label, phase 2 trial done in 42 Italian academic and community practice centres. We enrolled transplant-eligible patients with newly diagnosed multiple myeloma aged 65 years or younger with a Karnofsky Performance Status of 60% or higher. Patients were stratified according to International Staging System stage (I vs II/III) and age (

Published
2021

2. Whole-genome sequencing analysis of semi-supercentenarians

Author

Evelyn Ferri, Luciano Xumerle, Julien Marquis, Oliviero Olivieri, Gastone Castellani, Cristina Giuliani, Patrizia D'Aquila, Sandro Sorbi, Daniela Mari, Claudia Sala, Maria Giulia Bacalini, Paolo Garagnani, Patrick Descombes, Nicola Martinelli, Beatrice Arosio, Sebastiano Collino, Jérôme Carayol, Frederic Raymond, Benedetta Nacmias, Luca Bertamini, Davide Pettener, Domenico Girelli, Giuseppe Passarino, Vincenzo Iannuzzi, Katarzyna Malgorzata Kwiatkowska, Martina Casati, Donata Luiselli, Claudio Franceschi, Daniela Monti, Massimo Delledonne, Francesco De Rango, Elena Marasco, Armand Valsesia, Chiara Pirazzini, Alberto Ferrarini, Garagnani P., Marquis J., Delledonne M., Pirazzini C., Marasco E., Kwiatkowska K.M., Iannuzzi V., Bacalini M.G., Valsesia A., Carayol J., Raymond F., Ferrarini A., Xumerle L., Collino S., Mari D., Arosio B., Casati M., Ferri E., Monti D., Nacmias B., Sorbi S., Luiselli D., Pettener D., Castellani G., Sala C., Passarino G., De Rango F., D'aquila P., Bertamini L., Martinelli N., Girelli D., Olivieri O., Giuliani C., Descombes P., and Franceschi C.

Subjects
0301 basic medicine, Male, DNA Repair, semi-supercentenarians, medicine.disease_cause, Genome, Germline, genomic, Cohort Studies, 0302 clinical medicine, 80 and over, genetics, Biology (General), media_common, Genetics, Aged, 80 and over, Mutation, geroscience, General Neuroscience, Longevity, General Medicine, sequencing, Middle Aged, 3. Good health, Italy, ageing, clonal hematopoiesis, genomics, human, longevity, Cohort, Medicine, Female, Genetic Background, Research Article, QH301-705.5, DNA repair, Science, media_common.quotation_subject, semi-supercentenarian, Genomics, Biology, General Biochemistry, Genetics and Molecular Biology, 03 medical and health sciences, medicine, Humans, Aged, Whole genome sequencing, General Immunology and Microbiology, Whole Genome Sequencing, Genetics and Genomics, 030104 developmental biology, Clonal Hematopoiesi, genetic, Cohort Studie, 030217 neurology & neurosurgery
Abstract

Extreme longevity is the paradigm of healthy aging as individuals who reached the extreme decades of human life avoided or largely postponed all major age-related diseases. In this study, we sequenced at high coverage (90X) the whole genome of 81 semi-supercentenarians and supercentenarians [105+/110+] (mean age: 106.6 ± 1.6) and of 36 healthy unrelated geographically matched controls (mean age 68.0 ± 5.9) recruited in Italy. The results showed that 105+/110+ are characterized by a peculiar genetic background associated with efficient DNA repair mechanisms, as evidenced by both germline data (common and rare variants) and somatic mutations patterns (lower mutation load if compared to younger healthy controls). Results were replicated in a second independent cohort of 333 Italian centenarians and 358 geographically matched controls. The genetics of 105+/110+ identified DNA repair and clonal haematopoiesis as crucial players for healthy aging and for the protection from cardiovascular events.

Published
2021

3. Safety profile and impact on survival of tyrosine kinase inhibitors versus conventional therapy in relapse or refractory FLT3 positive acute myeloid leukemia patients

Author

Maria Teresa Bochicchio, Michele Cavo, Sarah Parisi, Carmen Baldazzi, Chiara Sartor, Giovanni Martinelli, Jacopo Nanni, Simone Ragaini, Matteo Olivi, Nicoletta Testoni, Stefano De Polo, Antonio Curti, Maddalena Raffini, Maria Chiara Fontana, Cristina Papayannidis, Emanuela Ottaviani, Francesca Bonifazi, Annalisa Talami, Gianluca Cristiano, Stefania Paolini, Mariachiara Abbenante, Giovanni Marconi, Luca Bertamini, Marconi G., De Polo S., Martinelli G., Nanni J., Bertamini L., Talami A., Olivi M., Ragaini S., Abbenante M.C., Sartor C., Ottaviani E., Bochicchio M.T., Parisi S., Fontana M.C., Cristiano G., Raffini M., Baldazzi C., Testoni N., Bonifazi F., Paolini S., Curti A., Cavo M., and Papayannidis C.

Subjects
Oncology, Adult, Male, Cancer Research, medicine.medical_specialty, Survival, Adolescent, medicine.medical_treatment, Antineoplastic Agents, Disease, Disease-Free Survival, 03 medical and health sciences, 0302 clinical medicine, Refractory, AML, Internal medicine, hemic and lymphatic diseases, Medicine, Chemotherapy, Humans, Adverse effect, FLT3, Protein Kinase Inhibitors, Aged, business.industry, Surrogate endpoint, Myeloid leukemia, Retrospective cohort study, Hematology, Middle Aged, TKI, respiratory tract diseases, Survival Rate, Leukemia, Myeloid, Acute, fms-Like Tyrosine Kinase 3, 030220 oncology & carcinogenesis, Mutation, Quality of Life, Neoplastic cell, Female, Safety, business, 030215 immunology
Abstract

Relapsed or refractory (R/R) acute myeloid leukemia (AML) has a poor prognosis, and new therapies are a major clinical need. When mutated, FLT3 drives neoplastic cell proliferation. New drugs (i.e., tyrosine kinase inhibitors, TKIs) showed effectiveness in FLT3-AML and promise to change disease history and outcome. We evaluated the benefit conferred by TKIs in terms of survival, burden of complications and surrogate endpoint of quality of life in a retrospective cohort of 49 FLT3 positive, R/R AML patients. Patients who received TKIs were compared to those treated with conventional chemotherapy. Treatment with TKIs conferred a better OS and wea associated with a lower burden and severity of adverse events. Importantly, patients who received TKIs showed reduced time of hospitalization. In conclusion, treatment with TKI in R/R FLT3-AML was related to a better survival, less and milder AEs, and shorter hospitalization.

Published
2020

Catalog

Books, media, physical & digital resources
See catalog results